Gempaz M 12.5mg /1000mg Tablet

Gempaz M 12.5mg/1000mg Tablet is a combination medication containing two active ingredients: Empagliflozin & Metformin Hydrochloride (HCl). Empagliflozin belongs to a class of medications called sodium-glucose cotransporter 2 (SGLT2) inhibitors, while Metformin HCl is a biguanide antidiabetic agent. This combination is used to treat type 2 diabetes mellitus by helping to lower blood sugar levels through different mechanisms of action.

Uses:

• Type 2 diabetes mellitus: Gempaz M Tablet is prescribed for the management of type 2 diabetes mellitus in adults. It helps improve glycemic control by reducing blood glucose levels through increased urinary glucose excretion (Empagliflozin) and decreased hepatic glucose production and improved insulin sensitivity (Metformin HCl).
• Blood sugar control: The combination of Empagliflozin and Metformin HCl in Gempaz M Tablet helps lower fasting and postprandial blood sugar levels, thereby reducing the risk of diabetes-related complications.
• Cardiovascular protection: Empagliflozin has been shown to provide cardiovascular benefits by reducing the risk of cardiovascular events, such as heart attack, stroke, and cardiovascular death, in patients with type 2 diabetes mellitus and established cardiovascular disease.

Side Effects:

• Common side effects of Gempaz M 12.5mg/1000mg Tablet may include:
  • Urinary tract infections
  • Genital yeast infections
  • Increased urination
  • Nausea or vomiting
  • Diarrhea
  • Headache
• Serious but rare side effects may include hypoglycemia (low blood sugar), ketoacidosis (high levels of ketones in the blood), or allergic reactions. Contact your healthcare provider promptly if you experience any severe or persistent side effects.

Precautions:

• Take Gempaz M 12.5mg/1000mg Tablet exactly as prescribed by your healthcare provider.
• Inform your doctor about any pre-existing medical conditions, especially kidney or liver disease, heart failure, or a history of diabetic ketoacidosis, before starting Empagliflozin and Metformin therapy.
• Monitor your blood sugar levels regularly while taking Gempaz M Tablet, and report any significant changes or episodes of hypoglycemia to your healthcare provider.
• Stay well-hydrated and maintain adequate fluid intake while on Empagliflozin therapy to reduce the risk of dehydration and related complications.

When Not to Use:

Avoid using Gempaz M 12.5mg/1000mg Tablet if:

• You have a known allergy to Empagliflozin, Metformin HCl, or any other ingredients in the tablet.
• You have severe kidney impairment (eGFR less than 30 mL/min/1.73 m²) or end-stage renal disease (ESRD), as Empagliflozin may not be recommended in these patients.
• You are pregnant, planning to become pregnant, or breastfeeding without consulting your healthcare provider.